Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2025

Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2025

## **Supplementary Information**

Design of Pyrrolo[2,3-d]Pyrimidine-Endoperoxide Hybrids as First-in-Class Dual Degraders of Cyclin D1/3 and CDK4/6 with Potent Antiproliferative Effects

Zhen Cui, <sup>a</sup> Yuanli Yang, <sup>a</sup> Changqi Wang, <sup>a</sup> Jiayi Zhu, <sup>a</sup> Haowei Jiao, <sup>a</sup> Lu Wang, <sup>b</sup> Silong Zhang, <sup>\*a,c</sup> Huan He, <sup>\*a,c</sup> and Hang Zhong <sup>\*a,c</sup>

- a. School of Pharmaceutical Sciences/ Guizhou Engineering Laboratory for Synthetic Drugs, Guizhou University, Guiyang, 550025, China.
- b. Chemical Engineering Center, Guizhou University, Guiyang, 550025, China
- c. Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Zunyi Medical University, Zunyi, 563000, China

E-mail address: hzhong\_gzu\_edu@126.com (H. Zhong)




Fig. S1 Dose-response curve of target compound in T47D cells. (New)




Fig. S2 Dose-response curve of target compound in MCF-7 cells. (New)




Fig. S3 Dose-response curve of target compound in MCF-10A cells. (New)




Fig. S4 <sup>1</sup>H NMR spectra of **a2**. (New)




Fig. S5 <sup>1</sup>H NMR spectra of **a4**. (New)




Fig. S6 <sup>1</sup>H NMR spectra of **a5**. (New)




Fig. S7 <sup>1</sup>H NMR spectra of **a6**. (New)




Fig. S8 <sup>1</sup>H NMR spectra of C1.




Fig. S9 <sup>1</sup>H NMR spectra of C2.




Fig. S10 <sup>1</sup>H NMR spectra of **D1**.




Fig. S11 <sup>1</sup>H NMR spectra of **D2**.




Fig. S12 <sup>1</sup>H NMR spectra of E1.




Fig. S13 <sup>1</sup>H NMR spectra of **E2**.




Fig. S14 <sup>13</sup>C NMR spectra of C1.




Fig. S15 <sup>13</sup>C NMR spectra of C2.




Fig. S16 <sup>13</sup>C NMR spectra of **D1**.




Fig. S17 <sup>13</sup>C NMR spectra of **D2**.




Fig. S18 <sup>13</sup>C NMR spectra of E1.




Fig. S19 <sup>13</sup>C NMR spectra of **E2**.




Fig. S20 HRMS spectra of C1




Fig. S21 HRMS spectra of C2




Fig. S22 HRMS spectra of **D1** 




Fig. S23 HRMS spectra of **D2** 




Fig. S24 HRMS spectra of E1




Fig. S25 HRMS spectra of E2




Fig. S26 The raw images of Western blot. Expression of Cyclin D1/3 and CDK4/6 in T47D cells following **E2** treatment. A) Changes in protein expression with different **E2** concentrations; B) Protein expression levels at various time intervals after treatment with 5  $\mu$ M **E2**.




Fig. S27 The raw images of Western blot. Expression of Cyclin D1/3 and CDK4/6 in T47D cells after treatment with 5  $\mu$ M **E2** alone or in combination with MG132. (New)